List of works - Mario Nuvolone

A neuroprotective role for microglia in prion diseases

scientific article published on 16 May 2016

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

scientific article published on 14 September 2012

Altered Monoaminergic Systems and Depressive-like Behavior in Congenic Prion Protein Knock-out Mice

scientific article published in October 2015

Cells and prions: a license to replicate

scientific article published on 13 June 2009

Cystatin F is a biomarker of prion pathogenesis in mice

scientific article

Efficient amyloid A clearance in the absence of immunoglobulins and complement factors

scientific article published on 21 February 2013

Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture

scientific article

Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney.

scientific article published in September 2016

Extended characterization of the novel co-isogenic C57BL/6J Prnp-/- mouse line.

scientific article published in March 2017

Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis

scientific article published in 2024

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

scientific article published in March 2017

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

scientific article published on 08 January 2009

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

scientific article published on 25 July 2014

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

scientific article

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

scientific article

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis

scientific article published on 01 March 2017

Prion pathogenesis in the absence of NLRP3/ASC inflammasomes

scientific article (publication date: 2015)

Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier

scientific article published on 29 November 2018

Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling

scientific article

Prion protein and Abeta-related synaptic toxicity impairment

scientific article

Prognostication of survival and progression to dialysis in AA amyloidosis

scientific article published on 01 March 2017

Regulated expression of amyloidogenic immunoglobulin light chains in mice

SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells

scientific article published on 21 October 2013

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

scientific article published on 30 April 2011

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

scientific article published on 01 March 2017

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

scientific article published on 06 June 2019

Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science

scientific article published on 29 February 2016

Structure-based drug design identifies polythiophenes as antiprion compounds

scientific article

Systemic amyloidosis: novel therapies and role of biomarkers

scientific article published on 18 August 2016

The Priority position paper: Protecting Europe's food chain from prions

scientific article

The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease

scientific article published on November 2012

The immunobiology of prion diseases

scientific article

The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6

scientific journal article

The role of the NADPH oxidase NOX2 in prion pathogenesis

scientific article

The workings of the amyloid diseases

scientific article published on January 2007

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

scientific article

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

scientific article published on 01 July 2007

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis

scientific article published on 01 March 2017

List of works by Mario Nuvolone

A neuroprotective role for microglia in prion diseases

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Altered Monoaminergic Systems and Depressive-like Behavior in Congenic Prion Protein Knock-out Mice

Cells and prions: a license to replicate

Cystatin F is a biomarker of prion pathogenesis in mice

Efficient amyloid A clearance in the absence of immunoglobulins and complement factors

Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture

Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney.

Extended characterization of the novel co-isogenic C57BL/6J Prnp-/- mouse line.

Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis

Prion pathogenesis in the absence of NLRP3/ASC inflammasomes

Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier

Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling

Prion protein and Abeta-related synaptic toxicity impairment

Prognostication of survival and progression to dialysis in AA amyloidosis

Regulated expression of amyloidogenic immunoglobulin light chains in mice

SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science

Structure-based drug design identifies polythiophenes as antiprion compounds

Systemic amyloidosis: novel therapies and role of biomarkers

The Priority position paper: Protecting Europe's food chain from prions

The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease

The immunobiology of prion diseases

The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6

The role of the NADPH oxidase NOX2 in prion pathogenesis

The workings of the amyloid diseases

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis